# RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

> **NCT07492316** · PHASE1 · RECRUITING · sponsor: **University of Florida** · enrollment: 24 (estimated)

## Conditions studied

- Recurrent Medulloblastoma

## Interventions

- **BIOLOGICAL:** Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)

## Key facts

- **NCT ID:** NCT07492316
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2030-09-01
- **Final completion:** 2031-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492316, "RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07492316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*